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Abstract: Checkpoint inhibitor-induced side effects such as diarrhea and colitis occur in up to 30% of
patients. We present a case of recurrent episodes of checkpoint inhibitor-induced colitis and subsequent
Fournier gangrene that resolved after ileostomy formation. Once the Fournier gangrene and colitis had
resolved, the ileostomy was reversed. However, within only 4 days, another serious flare-up of colitis
occurred, necessitating emergent re-formation of the ileostomy. Expertise in the management of side
effects of immune checkpoint inhibitor therapy is currently limited. Although most side effects are mild
to moderate and transient, a minority of patients suffer from life-threatening complications, such as
colitis. The creation of an ileostomy might be a valid treatment option in severe or recurrent colitis
due to immune checkpoint inhibitor therapy. Intestinal diversion surgery may be useful if conservative
treatment has failed, similar to other forms of immune-mediated intestinal inflammation.
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Summary: Checkpoint inhibitor–induced side effects such as diarrhea
and colitis occur in up to 30% of patients. We present a case of
recurrent episodes of checkpoint inhibitor–induced colitis and sub-
sequent Fournier gangrene that resolved after ileostomy formation.
Once the Fournier gangrene and colitis had resolved, the ileostomy
was reversed. However, within only 4 days, another serious flare-up of
colitis occurred, necessitating emergent re-formation of the ileostomy.
Expertise in the management of side effects of immune checkpoint
inhibitor therapy is currently limited. Although most side effects are
mild to moderate and transient, a minority of patients suffer from life-
threatening complications, such as colitis. The creation of an ileostomy
might be a valid treatment option in severe or recurrent colitis due to
immune checkpoint inhibitor therapy. Intestinal diversion surgery may
be useful if conservative treatment has failed, similar to other forms of
immune-mediated intestinal inflammation.
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Immune checkpoint inhibitors (ICIs), such as programmedcell death protein-1 and programmed death-ligand 1, are
monoclonal antibodies that block coinhibitory receptors on
T cells to activate their cytotoxic immune function. The
number of indications for ICI treatment is rising across various
tumor types, with sophisticated treatment regimens being devel-
oped. Unfortunately, optimum treatment of the side effects has
not been fully clarified or standardized so far.
The rate of ICI-induced autoimmune-type side effects
is described in up to 96% of patients, and in 17%–59%, these
are serious or life-threatening.1
Diarrhea is a very frequent side effect and occurs in up to
30% of patients, but is mostly of a less severe grade.2,3 Diarrhea
of grade 3–4 occurs in <10%, and clinically significant colitis is
even less common, with an incidence of 5%.4,5
The incidence is higher in patients receiving cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4)-blocking anti-
bodies, such as ipilimumab, compared with patients receiving
programmed cell death protein-1 receptor inhibitors, for
example, pembrolizumab or nivolumab, which cause grade
3–4 diarrhea in only 1%–2%.2,6,7
Ipilimumab is a human immunoglobulin G1 monoclonal
antibody that binds to CTLA-4, and enterocolitis is among the
most frequent immune-related adverse event associated with its
use. Diarrhea occurs in about one third of patients treated with
ipilimumab, whereas colitis is observed in up to 22% of patients.8
The clinical picture of ICI-induced colitis is similar to
severe acute colitis occurring in inflammatory bowel disease
(IBD) and is defined as diarrhea combined with either abdominal
pain, rectal bleeding, or mucus in stools.1,3 It—that is, IBD may
evolve into a life-threatening condition, leading to an acute
abdomen, sepsis, and the requirement for surgical intervention.3,6
Current recommendations advocate interrupting
treatment with checkpoint inhibitors when either grade I
diarrhea is persistent or grade II diarrhea occurs.3 Non-
steroidal anti-inflammatory drugs should be avoided in
patients treated with anti-CTLA-4 agents, as they may also
lead to enterocolitis.8
However, the pharmacologic effects of ICI therapy last
for a long time, implying that side effects may occur long
after interruption or termination of treatment.9 Most cases of
diarrhea do not appear earlier than five weeks after treatment
initiation, even though ICI therapy maybe already fully active,
and can occur even weeks after termination of therapy.3,9
Treatment of colitis as a side effect of ICI therapy is similar
to the treatment of colitis in IBD. Initial therapy—after exclusion
of Clostridium difficile toxin and cytomegalovirus infection—
comprises high-dose corticosteroids for 4–6 weeks. If the patient
fails to respond to corticosteroids, therapy is escalated to tumor
necrosis factor-alpha receptor antagonists (such as infliximab)
or, more recently, anti-integrin therapy (vedolizumab); the
latter may also be effective in some patients with infliximab-
refractory ICI-associated colitis.1,3,10 Recent data suggest that
selective immunosuppressive therapy should be initiated even
earlier in the treatment schedule of ICI-associated colitis.10
However, one of the largest published cohorts concluded that
corticosteroid and infliximab therapy rarely leads to complete
resolution of colitis, with a success rate as low as 30%.11
CASE DESCRIPTION
Here, we present the case of a patient who developed ICI
(nivolumab)-associated colitis, which was cured by ileostomy
placement. After reversal of the ileostomy, the development of a
further episode of severe colitis made the formation of another
defunctioning ileostomy necessary, which led to rapid improvement
and subsequent resolution of the colitis.
A 54-year-old male patient had been diagnosed with meta-
static melanoma (initial stage IIIB) in 2016, and immunotherapy
with nivolumab (300mg) was established in November 2017. As
side effects, he developed hypothyroidism, which was medically
treated and, in the later course, severe xerostomia and stomatitis.
Because of disease progression, 350mg ipilimumab was added
8 months later as combined therapy with nivolumab (reduced to
120mg). Radiotherapy with 6×5Gy was performed due to brain
metastasis, for which the patient was also taking dexamethasone
4 mg twice a day. The first episode of colitis was treated with
infliximab and budesonide rectal foam (Fig. 1). In a subsequent
relapse, methylprednisolone 250mg over 3 days was added to the
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infliximab. He improved and could be discharged under 8 mg oral
dexamethasone and 2mg budesonide rectal foam.
In September 2018, a few days after discharge, he presented
with another episode of colitis. In addition to this, he showed acute
pancreatitis and again xerostomia as further side effects.
The colitis was treated with 250mg IV methylprednisolone
and 800mg IV tocilizumab (Fig. 1). With this therapy, the diarrheal
episodes initially improved in frequency, but, after 5 days, he
developed septic shock and multiorgan failure with a Fournier
gangrene, which he developed on the base of an anal fistula.
After the first surgical debridement and antibiotic treatment of
the Fournier gangrene, a diverting loop ileostomy was fashioned to
allow the local wound infection to heal.
The patient required treatment in the intensive care unit and
underwent 6 further debridements. After 1 month, the patient was
transferred to a rehabilitation facility. Colitis was not clinically
apparent at this stage. Because of wound necrosis, another 1-month
admission over 1-month operations was necessary.
Once complete recovery had occurred, 3 months after the
episode of Fournier gangrene, treatment with a checkpoint inhibitor
(nivolumab as a monotherapy) was re-established during which no
clinical features of colitis were apparent.
After 5 cycles of ICI treatment, the patient requested a
reversal of the ileostomy. During the preoperative workup for the
ileostomy reversal, a colonoscopy was performed, which showed no
signs of colitis (Fig. 2).
Few data exist with regard to postoperative complications in
patients receiving ICI therapy undergoing intestinal surgery.12 In
view of the lack of data, the indication for ileostomy closure was
discussed at and approved by a multidisciplinary tumor board. The
patient was informed about the proposed benefits of surgery but
based on little published evidence.
Closure of the ileostomy and the very early postoperative
course were uneventful. Three days after the stoma reversal, the
patient developed substantially increased inflammatory parameters
and severe abdominal pain in all quadrants. A computed tomog-
raphy scan showed free air and fluid, which was interpreted as
suspicious for anastomotic leakage. An emergent explorative lapa-
rotomy was performed. To our surprise, no failure of the ileal
anastomosis was found, but macroscopic evidence of severe colitis
was noted. For confirmation, an intraoperative colonoscopy was
performed, which confirmed severe colitis in all accessible segments
of the colon (Figs. 3, 4). We, therefore, decided to refashion the loop
ileostomy. The patient clinically began to stabilize on the first
postoperative day, and coagulation parameters, which had pre-
viously been abnormal due to the sepsis, normalized. C-reactive
protein values increased for another 2 days but then rapidly fell.
After the exclusion of C. difficile and cytomegalovirus colitis,
anti-inflammatory medication with 125mg IV methylprednisolone
for 6 days was administered. The patient made a full recovery and
was discharged in a good condition after 13 days. He was weaned
off the steroids over the succeeding 6 weeks.
DISCUSSION
ICI therapies are increasingly frequently used in the
treatment of different tumor types. Despite their impressive
efficacy profile, they can generate immune-related adverse
events, which appear to be life-threatening in up to 10% of
patients.13 To limit the severity and duration of side effects,
early identification and treatment are crucial. Related to the
immunologic mode of action, colitis induced by checkpoint
inhibitors presents clinically similarly to colonic Crohn
disease and ulcerative colitis.8
FIGURE 1. Therapeutic and clinical course of the patient. CT indicates computed tomography; ICI, immune checkpoint inhibitor; PET,
positron emission tomography.
FIGURE 2. Preoperative colonoscopy without any signs of colitis.
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As well as the clinical presentation, medical treatment
regimens are also comparable to those used in chronic IBD,
suggesting that the underlying pathophysiology is similar.
ICI-associated colitis may necessitate high doses of steroids
followed by immunomodulators or biologics if the former
has insufficient efficacy. As shown in a recent cohort from
Australia, a sizable number of patients with acute severe
colitis do not achieve resolution with medical treatment and
require surgical intervention, such as a total colectomy and
formation of an end ileostomy.11
It is well known that stool diversion surgery is effective
in helping to improve an acute episode of inflammatory
colitis, and one study showed that, instead of an emergent
colectomy in IBD patients, the formation of a defunctioning
loop ileostomy could be performed as an alternative.14 In
contrast, other authors suggest performing a subtotal rather
than segmental colectomy, as anti-CTLA-4-induced colitis
affects the entire colon.8 However, two out of three patients
with partial colectomy in the latter study had a colostomy
formed after segmental resection and therefore no stool
diversion was required. Furthermore, all of these patients had
to be operated because of perforation or toxic megacolon.8
We retrospectively assume that the formation of the
ileostomy during the episode of Fournier gangrene helped
settle the colitis that flared up again after the ileostomy was
reversed. That the colitis improved a second time after
repeating the surgery reinforces this hypothesis.
As previously shown, ICI-induced colitis is treated pri-
marily with corticosteroids. However, there is emerging evi-
dence that severe opportunistic infections can occur when
steroids are administered for the treatment of ICI-induced side
effects.13,15 Although causality is unproven in this case, our
patient was receiving corticosteroids when he developed
Fournier gangrene and that this is an opportunistic condition
that seems highly likely. The administration of corticosteroids
was stopped after the diagnosis of Fournier gangrene
was made.
Immune checkpoints are known to be immune exhaustion
markers due to their effect in downmodulating T-cell activation
and proliferation.13,16 In chronic infections, immune checkpoints
are regularly upregulated to avoid an excessive immune
response.13,16 Treatment against inhibitory immune checkpoints
consequently results in an increase in immune system activity.2
Despite their very different approaches, steroids lead to immu-
nosuppression and ultimately produce a similar effect to immune
checkpoint activation in such a setting.13,17
Until now, there is no evidence that the implementa-
tion of immunosuppression has a detrimental effect on the
efficacy of checkpoint inhibitor therapy, even though it
would theoretically appear likely.13,17
To the best of our knowledge, the creation of an ileostomy
to allow the resolution of ICI-induced colitis has not been
described in the literature so far. There are only a few case
reports about ileostomy formation after colonic perforation and
septic shock in ICI-associated colitis, as each case had a poor
outcome.18,19 However, colonic perforation in an immunosup-
pressed patient has known high mortality, and the outcome
cannot be compared with prophylactic ileostomy formation, a
procedure that is intended to prevent the disease in its early
stage developing further.
The fundamental difference between ICI-induced colitis
and IBD is that the former represents a side effect of essential
medical treatment. This means that there are 2 conflicting
perspectives: it would be advisable to discontinue therapy with
ICIs in severe colitis to minimize infective complications, but,
from an oncological point of view, it would be preferable to
continue ICI therapy. More data and further research are
needed to test the hypothesis that ileostomy formation in acute
severe colitis could avoid further complications from immu-
nosuppressive medication or even discontinuation of the ICI
therapy, especially when severe inflammation more proximally
in the gastrointestinal tract is not present.20,21 However, on the
basis of our experience in this case, we believe that the creation
of an ileostomy for stool diversion could represent a valuable
option for the treatment of severe ICI-induced colitis in the
future.
CONCLUSION
Expertise in the management of side effects of ICI
therapy is currently limited. Interruption or cessation of
checkpoint inhibitor therapy due to side effects, such as
severe colitis, should be discussed case by case. However, the
pharmacologic effects of ICI therapy may last for a long
time, meaning that side effects may not only occur a long
period after interruption or termination of the treatment but
also that cessation of therapy will become effective only
FIGURE 3. Intraoperative colonoscopy after stoma reversal
showed severe colitis, especially in the descending colon.
FIGURE 4. Intraoperative colonoscopy after stoma reversal
showed severe colitis, especially in the descending colon.
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after a significant period of time. Although most side effects
of checkpoint inhibitory therapy are mild to moderate and
transient, some patients may suffer from life-threatening
complications, such as colitis.
Creation of an ileostomy might, therefore, be a valid
treatment option in severe or recurrent colitis due to ICI therapy.
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